Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.
Chronic Myeloid Leukemia|Leukemia, Lymphoblastic, Acute, Philadelphia-positive
DRUG: Dasatinib
Major and overall hematologic response rates, throughout the study
Durability of hematologic response and time to hematologic response (major and overall), throughout the study|Assess cytogenetic and molecular responses, throughout the study|Measure minor hematologic response rate in the imatinib resistant group, throughout the study|Explore the role of BCR-ABL mRNA expression and point mutations in the BCR-ABL gene, throughout the study|Measure the heath-related QOL using FACT-G, throughout the study|To assess safety and tolerability of dasatinib, throughout the study|Population PK, first month
The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.